News Breaks |
|
|
| February 4, 2013 |
| 16:02 EDT |  | GEVA | Synageva announces publication of sebelipase alfa study
Synageva BioPharma announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency in the online version and an upcoming print edition of Hepatology. Nine adults with LAL Deficiency were enrolled in the Phase I/II trial. After completing the initial portion of the Phase I/II trial, patients were allowed to continue treatment with sebelipase alfa as part of a long-term, open-label extension study. In the extension study, patients received four once-weekly infusions of sebelipase alfa and then transitioned to every other week infusions of sebelipase alfa. Eight of nine patients enrolled in the extension study. Data published in Hepatology were derived from the seven patients who completed the first 12 weeks of dosing in the extension study. Sebelipase alfa was well tolerated throughout the initial 12 weeks of the extension study, the company said. |
|
|
News For GEVA From The Last 14 Days Check below for free stories on GEVA the last two weeks. |
|
|
| May 16, 2013 |
| 08:28 EDT |  | GEVA | Synageva has a conference call hosted by JPMorgan
 Subscribe for More Information |
|
| May 10, 2013 |
| 08:05 EDT |  | GEVA | Synageva downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Synageva citing concerns that the enrollment could be challenging for the sebelipase alfa Phase 3 trial. The firm lowered its price target for shares to $50 from $57. |
|
| May 9, 2013 |
| 07:15 EDT | | GEVA | Synageva's sebelipase alfa shows sustained effects and treatment tolerance
Subscribe for More Information |
|
| May 7, 2013 |
| 16:23 EDT | | GEVA | Synageva to initiate natural history study of SBC-103 by mid-year
Subscribe for More Information |
|
| 16:21 EDT |  | GEVA | Synageva reaffirms FY13 net operating loss view ($97M)-($87M)
Subscribe for More Information |
|
| 16:20 EDT | | GEVA | Synageva reports Q1 EPS (54c), consensus (70c)
Reports Q1 revenue $5.12M, consensus $2.56M. |
|
|
|
|
|
